US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities

Recommendation
18-20 November 2025
Practical approaches for assessing the risks of Impurities
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
16.04.2025EDQM: Excipient Monographs and Reference Standards
09.04.2025FDA Warning Letter: Missing Ongoing Stability Program for Biotech APIs
02.04.2025WHO: Update of Guideline of Reference Standards
26.03.2025EMA: Update of "PLM Portal eAF - Release Notes"
26.03.2025PFAS Restriction in the EU: Pharma Deutschland and VDDI request Comprehensive Exemptions